首页> 外文期刊>Human vaccines & immunotherapeutics. >Effectiveness of an Indian-made Attenuated influenza A(H1N1)pdm 2009 vaccine A case control study
【24h】

Effectiveness of an Indian-made Attenuated influenza A(H1N1)pdm 2009 vaccine A case control study

机译:印度制造的2009年减毒A(H1N1)pdm减毒流感疫苗的有效性病例对照研究

获取原文
获取原文并翻译 | 示例
       

摘要

A live attenuated influenza A(H1N1)pdm 2009 vaccine was developed and distributed in India in 2010. We estimated the vaccine effectiveness (VE) against laboratory-confirmed pandemic H1N1 (pH1N1) infections in patients with influenza-like illness who visited five tertiary care hospitals in Pune, India during June-December 2010. Swab specimens were analyzed for influenza pH1N1 by reverse transcriptase polymerase chain reaction (RT-PCR). VE was estimated using the test-negative case-control study design and logistic regression. A total of 784 patients (253 cases, 531 controls) were analyzed. The unadjusted overall VE was 75.5% (95% confidence interval [CI] 42.1-89.7), while the adjusted VE was 76% (95% CI 42.1-89.7). We conclude that the live attenuated influenza A(H1N1)pdm 2009 vaccine was effective in our study population, which has opened prospects for using this platform for trivalent formulations.
机译:于2009年开发了一种减毒活2009年A(H1N1)pdm活疫苗,并在印度分发。我们估计了对接受过五次三级护理的类流感患者的实验室确诊的H1N1大流行性流感(pH1N1)感染的疫苗有效性(VE) 2010年6月至12月,在印度浦那的一家医院中进行了研究。通过逆转录酶聚合酶链反应(RT-PCR)对拭子标本中的流感病毒pH1N1进行了分析。使用测试阴性的病例对照研究设计和logistic回归估算VE。总共分析了784例患者(253例,531例对照)。未经调整的总VE为75.5%(95%置信区间[CI] 42.1-89.7),而经过调整的VE为76%(95%CI 42.1-89.7)。我们得出的结论是,2009年减毒活流感A(H1N1)pdm减毒疫苗在我们的研究人群中有效,这为将该平台用于三价制剂开辟了前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号